Cargando…

Cost-effectiveness analysis of vonoprazan versus proton pump inhibitors in the treatment of reflux esophagitis in China

BACKGROUND: Proton pump inhibitors (PPIs) have been recommended as standard of care for reflux esophagitis (RE). Vonoprazan (VPZ), a novel potassium-competitive acid blocker (P-CAB), has been approved in China after demonstrating clinical benefit in RE. However, there are not any published literatur...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Zhenhua, Sun, Ruixiaotong, Sheng, Yanan, Qu, Shuli, Dong, Lu, Wu, Bin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096411/ https://www.ncbi.nlm.nih.gov/pubmed/35571388 http://dx.doi.org/10.21037/atm-22-1722

Ejemplares similares

Efficacy of vonoprazan for initial and maintenance therapy in reflux esophagitis, nonerosive esophagitis, and proton pump inhibitor-resistant gastroesophageal reflux disease
por: Gotoh, Yasuhiko, et al.
Publicado: (2020)

Efficacy of vonoprazan for 24-week maintenance therapy of patients with healed reflux esophagitis refractory to proton pump inhibitors
por: Mizuno, Hideki, et al.
Publicado: (2018)

Efficacy of Vonoprazan for Gastroesophageal Reflux Symptoms in Patients with Proton Pump Inhibitor-resistant Non-erosive Reflux Disease
por: Niikura, Ryota, et al.
Publicado: (2018)

Vonoprazan versus proton pump inhibitors for the management of gastroesophageal reflux disease: A protocol for a systematic review with meta-analysis
por: Kang, Hyun, et al.
Publicado: (2018)

Vonoprazan versus Lansoprazole for the Initial Treatment of Reflux Esophagitis: A Cost-effectiveness Analysis in Japan
por: Habu, Yasuki
Publicado: (2019)

Efficacy, safety and cost-effectiveness of vonoprazan vs Proton Pump Inhibitors in reflux disorders and H. pylori eradication: A literature review
por: Shehryar, Muhammad, et al.
Publicado: (2022)

The effect of proton pump inhibitors and vonoprazan on the development of ‘gastric mucosal redness’
por: Shinozaki, Satoshi, et al.
Publicado: (2022)

Evaluation of symptomatic reflux esophagitis in proton pump inhibitor users
por: Asaoka, Daisuke, et al.
Publicado: (2019)

Systematic review with network meta-analysis: indirect comparison of the efficacy of vonoprazan and proton-pump inhibitors for maintenance treatment of gastroesophageal reflux disease
por: Miwa, Hiroto, et al.
Publicado: (2019)

Comparative study: Vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy
por: Sakurai, Kouichi, et al.
Publicado: (2017)

Efficacy and safety of proton pump inhibitors versus vonoprazan in treatment of erosive esophagitis: A PRISMA-compliant systematic review and network meta-analysis
por: Yang, Sensen, et al.
Publicado: (2022)

The daily response for proton pump inhibitor treatment in Japanese reflux esophagitis and non-erosive reflux disease
por: Shida, Hiroshi, et al.
Publicado: (2013)

Anti-reflux Surgery Versus Proton Pump Inhibitors for Severe Gastroesophageal Reflux Disease: A Cost-Effectiveness Study in Korea
por: Park, Susan, et al.
Publicado: (2020)

Management of laryngopharyngeal reflux with proton pump inhibitors
por: Reimer, Christina, et al.
Publicado: (2008)

The Development of Foveolar-type Gastric Adenocarcinoma during Maintenance Therapy of Vonoprazan for Reflux Esophagitis
por: Saito, Masahiro, et al.
Publicado: (2020)

Real-world outcomes associated with vonoprazan-based versus proton pump inhibitor-based therapy for Helicobacter pylori infection in Japan
por: Howden, Colin W., et al.
Publicado: (2023)

Time esophageal pH < 4 overestimates the prevalence of pathologic esophageal reflux in subjects with gastroesophageal reflux disease treated with proton pump inhibitors
por: Gerson, Lauren B, et al.
Publicado: (2008)

Eosinophilic esophagitis in patients with typical gastroesophageal reflux disease symptoms refractory to proton pump inhibitor
por: de Sá, Cláudia Cristina, et al.
Publicado: (2011)

Can Esophageal Baseline Impedance Predict Proton Pump Inhibitor Response in Gastroesophageal Reflux Disease?
por: Jung, Kyoungwon, et al.
Publicado: (2018)

Recent effectiveness of proton pump inhibitors for severe reflux esophagitis: the first multicenter prospective study in Japan
por: Mizuno, Hideki, et al.
Publicado: (2015)

Vonoprazan versus proton pump inhibitors for the management of gastric endoscopic submucosal dissection-induced artificial ulcer: A systematic review with meta-analysis
por: Kang, Hyun, et al.
Publicado: (2019)

Effects of Proton Pump Inhibitors on the Gastrointestinal Microbiota in Gastroesophageal Reflux Disease
por: Shi, Yi-Chao, et al.
Publicado: (2019)

Helicobacter pylori, proton pump inhibitors and gastroesophageal reflux disease.
por: Kuipers, E. J., et al.
Publicado: (1999)

Effectiveness of vonoprazan-based regimens compared with proton pump inhibitor-based regimens as first-line Helicobacter pylori agents
por: Kakiuchi, Toshihiko
Publicado: (2023)

The role of vonoprazan in patients with erosive esophagitis
por: Zhang, Mengyu, et al.
Publicado: (2022)

Proton pump inhibitors for the treatment of patients with erosive esophagitis and gastroesophageal reflux disease: current evidence and safety of dexlansoprazole
por: Mermelstein, Joseph, et al.
Publicado: (2016)

A randomized, double-blind study to evaluate the acid-inhibitory effect of vonoprazan (20 mg and 40 mg) in patients with proton-pump inhibitor-resistant erosive esophagitis
por: Iwakiri, Katsuhiko, et al.
Publicado: (2017)

Upper Esophageal Sphincter Compression Device as an Adjunct to Proton Pump Inhibition for Laryngopharyngeal Reflux
por: Yadlapati, Rena, et al.
Publicado: (2021)

Proton pump inhibitor-refractory gastroesophageal reflux disease: challenges and solutions
por: Mermelstein, Joseph, et al.
Publicado: (2018)

Meta-analysis of the efficacy of proton pump inhibitors for the symptoms of laryngopharyngeal reflux
por: Liu, C., et al.
Publicado: (2016)

Meta-analysis of Proton Pump Inhibitors in the Treatment of Pharyngeal Reflux Disease
por: Jin, Xiulin, et al.
Publicado: (2022)

Efficacy and Safety of Vonoprazan-Based versus Proton Pump Inhibitor-Based Triple Therapy for Helicobacter pylori Eradication: A Meta-Analysis of Randomized Clinical Trials
por: Lyu, Qiu-Ju, et al.
Publicado: (2019)

Randomized Controlled Trial of Anti-reflux Mucosectomy Versus Radiofrequency Energy Delivery for Proton Pump Inhibitor-refractory Gastroesophageal Reflux Disease
por: Wang, Yan, et al.
Publicado: (2023)

Clinical value of wireless pH-monitoring of gastro-esophageal reflux in children before and after proton pump inhibitors
por: Boström, Michaela, et al.
Publicado: (2014)

Role of altered esophageal intraluminal baseline impedance levels in patients with gatroesophageal reflux disease refractory to proton pump inhibitors
por: Jiang, Liuqin, et al.
Publicado: (2016)

Trends in proton pump inhibitor use, reflux esophagitis, and various upper gastrointestinal symptoms from 2010 to 2019 in Japan
por: Yamamichi, Nobutake, et al.
Publicado: (2022)

Eosinophilic Esophagitis on and off Proton Pump Inhibitor
por: Zimmer, Vincent, et al.
Publicado: (2023)

Use of vonoprazan for management of systemic sclerosis-related gastroesophageal reflux disease
por: Tabuchi, Maiko, et al.
Publicado: (2021)

Role of Acid and Weakly Acidic Reflux in Gastroesophageal Reflux Disease Off Proton Pump Inhibitor Therapy
por: Sung, Hea Jung, et al.
Publicado: (2012)

Comparison of the Use of Vonoprazan and Proton Pump Inhibitors for the Treatment of Peptic Ulcers Resulting from Endoscopic Submucosal Dissection: A Systematic Review and Meta-Analysis
por: He, Hui-Si, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_6p734v6jh7965gdnv87c5nlj1a